Kestra Medical Technologies device for detecting and responding to cardiac events. (Kestra Photo)Kestra Medical Technologies, a Kirkland, Wash.-based company selling cardiac monitoring and therapeutic devices, filed for an initial public offering on Monday.The company’s revenue more than tripled from $7.6 million in fiscal year 2023 to $27.8 million in the last fiscal year, which ended in April. Net losses for the same periods were $84.2 million in 2023 and $94.1 million last year, according to a filing with the U.S. Securities and Exchange Commission.Monday’s filling marks the end of a long dry stretch with no traditional IPOs for Seattle-area tech companies since Sana Biotechnology went public in 2021. Companies have gone public since that time via a special purpose acquisition company (SPAC), the most recent being Longevity Biomedical in 2023. This follows a broader trend that saw a surge in U.S

SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Wednesday, January 15, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer

Fast Track designation is designed to expedite clinical development and regulatory review timelinesEnrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including systemic lupus erythematosus; expect to report initial clinical data in 2025SEATTLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for SC291 in relapsed/refractory systemic lupus erythematosus (SLE), which includes extrarenal lupus and lupus nephritis. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.SC291, a hypoimmune (HIP)-modified CD19-directed allogeneic CAR T therapy, is being evaluated in Sana’s GLEAM trial in patients with B-cell mediated autoimmune diseases including lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Sana is enrolling patients in this study and expects to share initial data in 2025.“We are pleased to receive Fast Track designation from the FDA for SC291, which highlights the need for new treatment options for patients with relapsed/refractory SLE,” said Dhaval Patel, M.D., Ph.D., Chief Scientific Officer of Sana